Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novozymes Biopharma, part of Novozymes, has released new data which demonstrates extended shelf life of protein drug products using recombinant human albumin Recombumin. The data reveals the potential of Recombumin to reduce product loss by preventing the physical and chemical degradation of protein drugs.
Subscribe to our email newsletter
Derived from Novozymes Biopharma’s proprietary yeast expression technology, Recombumin is the animal-free, commercially available recombinant human albumin used in the manufacture of licensed and developmental human therapeutics.
Novozymes Biopharma said that the study investigated the ability of Recombumin, a recombinant human albumin expressed in Saccharomyces cerevisiae, to prevent the deterioration of protein drug products in a variety of test formulations. The study particularly addressed Recombumin’s minimisation of surface adsorption, oxidation and aggregation in comparison to excipients commonly used for the purpose of formulating protein drugs.
The new data demonstrates that Recombumin has the capacity to improve the shelf life of protein drug products. The study’s findings indicate that Recombumin performed as well as and often better than the comparators making it an effective multi-purpose excipient with the capability to reduce the total number of excipients required and therefore simplifying the formulation strategy.